Cell substrates for the production of viral vaccines

作者: Françoise Aubrit , Fabien Perugi , Arnaud Léon , Fabienne Guéhenneux , Patrick Champion-Arnaud

DOI: 10.1016/J.VACCINE.2015.06.110

关键词: CellBusinessVaccine ProductionCell cultureChikungunyaCell substrateProduction (economics)VirologyViral VaccinePandemicPublic Health, Environmental and Occupational HealthGeneral Immunology and MicrobiologyMolecular medicineGeneral VeterinaryInfectious Diseases

摘要: Vaccines have been used for centuries to protect people and animals against infectious diseases. For vaccine production, it has become evident that cell culture technology can be considered as a key milestone the result of decades progress. The development implementation substrates permitted massive safe production viral vaccines. demand in new vaccines emerging diseases, increasing volumes, stringent safety rules manufacturing made mandatory producer factories. In this review, we focus on human Depending nature vaccine, choice substrate is critical. Each manufacturer intending develop candidate should assess several during early phase order select most convenient application. First, quite naturally central concern Regulatory Agencies, answer regulatory stringency. addition, competitive terms viral-specific yields costs. No substrate, even so-called "designer" lines, able fulfil all requested criteria Therefore, availability variety essential because improves chance successfully respond current future needs linked or re-emerging diseases (e.g. pandemic flu, Ebola, Chikungunya outbreaks).

参考文章(80)
Yvonne Genzel, Jana Rödig, Erdmann Rapp, Udo Reichl, Vaccine production: upstream processing with adherent or suspension cell lines. Methods of Molecular Biology. ,vol. 1104, pp. 371- 393 ,(2014) , 10.1007/978-1-62703-733-4_23
G M Farris, A B Barnum, W W Nichols, L B Harper, C A Anderson, G Balasubramanian, J A Lebronl, R K Kemp, N T Gatto, E R Brown, J B Coleman, K L Mauer, C L Lanning, L A Gumprecht, J A Lewis, P F J Troilo, B J Ledwith, S J Pacchione, J J Wolf, Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Developments in biologicals. ,vol. 123, pp. 251- 263 ,(2006)
Jonas E. Salk, P. L. Bazeley, Byron L. Bennett, Ulrich Krech, L. James Lewis, Elsie N. Ward, J. S. Youngner, II. A Practical Means for Inducing and Maintaining Antibody Formation American Journal of Public Health and the Nations Health. ,vol. 44, pp. 994- 1009 ,(1954) , 10.2105/AJPH.44.8.994
Sandra Coecke, Michael Balls, Gerard Bowe, John Davis, Gerhard Gstraunthaler, Thomas Hartung, Robert Hay, Anna Price, Otto-Wilhelm Merten, William Stokes, Leonard Schechtman, Glyn Stacey, Guidance on Good Cell Culture Practice Springer, Dordrecht. pp. 313- 315 ,(2007) , 10.1007/978-1-4020-5476-1_49
Nicolas Seve, Eric Calvosa, Process for culturing adherent cells ,(2010)
Jennifer M Audsley, Gregory A Tannock, Cell-based influenza vaccines: progress to date. Drugs. ,vol. 68, pp. 1483- 1491 ,(2008) , 10.2165/00003495-200868110-00002
Chris Yallop, John Crowley, Johanne Cote, Kirsten Hegmans-Brouwer, Fija Lagerwerf, Rodney Gagne, Jose Coco Martin, Nico Oosterhuis, Dirk-Jan Opstelten, Abraham Bout, PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins Modern Biopharmaceuticals: Design, Development and Optimization. pp. 779- 807 ,(2008) , 10.1002/9783527620982.CH33
Anthony S. Lubiniecki, Historical reflections on cell culture engineering Cytotechnology. ,vol. 28, pp. 139- 145 ,(1998) , 10.1023/A:1008094017583